Paper Details
- Home
- Paper Details
Testicular pain following initiation of elexacaftor/tezacaftor/ivacaftor in males with cystic fibrosis.
Author: DuehlmeyerStephanie, HeckmanBrian, JacobsHollyann R, RotoloShannon M, SlackSarah M
Original Abstract of the Article :
Elexacaftor/tezacaftor/ivacaftor (Trikafta) was approved by the Food and Drug Administration in October 2019 for treatment of cystic fibrosis (CF) in patients 12 years and older with at least one F508del mutation in the CFTR protein. There were no documented reports of testicular pain during clinica...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1016/j.jcf.2020.04.017
データ提供:米国国立医学図書館(NLM)
Testicular Pain Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Males with Cystic Fibrosis
This case series explores the occurrence of testicular pain in seven males with cystic fibrosis (CF) after initiating treatment with elexacaftor/tezacaftor/ivacaftor (Trikafta). While clinical trials did not document testicular pain as a side effect, these patients experienced this symptom within the first two weeks of starting Trikafta. The authors speculate that the pain might be related to the restored function of the CFTR protein in the male reproductive tract.
Unforeseen Side Effects: A Desert of Uncertainty
While Trikafta has shown significant promise in treating CF, this case series highlights a potential side effect that needs further investigation. The authors caution that the mechanism of this side effect is unknown and requires further research. They also recommend counseling patients on contraceptive options until more data is available.
Navigating the Landscape of New Treatments
It's like exploring a new desert landscape, where the terrain is constantly shifting and surprises can emerge at every turn. Just as a camel must adapt to its surroundings, we must constantly learn and adapt to new treatments and their potential side effects. While Trikafta offers hope for CF patients, it's important to remain vigilant and continue to monitor its long-term impact, ensuring that the benefits outweigh the risks. By learning from these experiences, we can optimize the use of new treatments and ensure the safety and well-being of all patients.
Dr.Camel's Conclusion
This case series highlights the importance of ongoing surveillance for potential side effects of new treatments, even those that have shown promise in clinical trials. The authors' findings underscore the need for further research to understand the mechanism of this side effect and its long-term implications. This information will be crucial for guiding clinical decision-making and ensuring the safety and well-being of patients receiving Trikafta.
Date :
- Date Completed 2021-10-19
- Date Revised 2021-11-16
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.